Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2025-09-11 Share Issue/Capital Cha…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Share Issue/Capital Change 2025
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding an increase in share capital due to the exercise of employee warrants. This falls under the category of share capital changes or new share issues. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the correct classification for announcements regarding new share issues or capital changes.
2025-09-11 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding a change in major shareholding (Van Herk Investments B.V. crossing a threshold). It explicitly identifies itself as a 'major shareholder announcement' and provides details on the percentage of share capital and voting rights held. This aligns perfectly with the definition for Major Shareholding Notification (MRQ).
2025-08-20 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' regarding Zealand Pharma A/S. It explicitly details the crossing of a shareholding threshold (from 10.001% to 9.973%) by Van Herk Investments B.V. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which tracks changes in significant ownership levels.
2025-08-20 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' which explicitly details the acquisition or disposal of voting rights and share capital in Zealand Pharma A/S. It identifies the shareholder (Van Herk Investments B.V.), the threshold crossed, and provides the required regulatory disclosure format for major shareholding notifications. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-08-20 English
Earnings Release 2025
Earnings Release Classification · 100% confidence The document is a formal announcement from Zealand Pharma regarding their financial results for the first half of 2025. It includes key financial highlights, operational updates, and forward-looking statements. While it contains financial data, it is structured as an initial announcement of results (Earnings Release) rather than a full, comprehensive interim report. It also provides details for an upcoming conference call, which is standard for an earnings release. H1 2025
2025-08-14 English
Earnings Release 2025
Earnings Release Classification · 100% confidence The document is an official announcement from Zealand Pharma regarding their financial results for the first half of 2025. It includes key financial highlights, operational updates, and forward-looking statements. While it contains financial data, it is structured as a press release/announcement of interim results rather than a full, comprehensive interim report (which would typically be a longer, more formal regulatory filing). Given the format, length, and content, it fits the definition of an Earnings Release (ER). H1 2025
2025-08-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.